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Transmission of drug-resistant pathogen
strains is an almost universal threat to
treatment success in individual patients
and to the utility of drugs at the popula-
tion level. In the case of human immuno-
deﬁciency virus (HIV) in resource-rich
settings, a combination of measures—
including baseline resistance testing, po-
tent regimens with high genetic barrier,
close surveillance of therapy success,
and introduction of new drug classes—
has been uniquely successful in restrict-
ing the prevalence of transmitted drug
resistance (TDR) to levels below 10%–
15% [1–3]. Going beyond this success
and completely eradicating the transmis-
sion of drug-resistant HIV has, however,
proven to be challenging so far: Overall
levels of HIV TDR in industrialized coun-
trieshavedecreasedonlyweaklyornot at all
over the last 15 years despite strong reduc-
tions of the frequency of therapy failure
and of the emergence of drug resistance
in treated individuals [2, 4]. This pattern
can be explained by the hypothesis that
by now, in these settings, untreated pa-
tients are the major source of HIV TDR
[5]. Thus, drug-resistant strains can main-
tain themselves in the untreated popula-
tion and are thereby not dependent on
treatment failure. A key factor in this pro-
cess are the slow reversion rates of many
TDR mutations, which in turn are due to
their low ﬁtness costs [6, 7]. Accordingly,
clear decreases in TDR have been observed
for high-ﬁtness-cost nucleoside reverse
transcriptase inhibitor (NRTI) mutations
such as M184V [2]. These mutations
revert quickly in the absence of drug pres-
sure and hence disappear as TDR as soon
as they no longer emerge in treatment-
failing patients. However, such high-cost
mutations have never been very frequent
among TDR HIV, and have almost van-
ished in the course of the recent treatment
improvements. As a consequence, the bulk
of TDR is composed of low-cost muta-
tions that can successfully circulate in
treatment-naive patients.
The study by Mbisa et al [8], in the cur-
rent issue of Clinical Infectious Diseases,
tests and eventually strengthens this hy-
pothesis by using phylogenetic and phylo-
dynamic approaches to analyze HIV type
1 subtype B sequence data from the UK
HIV Drug Resistance Database, one of the
most representative databases of its kind.
The phylogenetic analysis goes beyond
the standard description of prevalence of
resistance mutations by capturing their
occurrence in the context of the transmis-
sion network. This relies on the intuition
that viruses that are close on the phylogeny
are likely to be close on the transmission
chain. Hence, in well-sampled popula-
tions, the closest neighbors on a phyloge-
ny are potential transmission sources.
Accordingly, an isolated occurrence of
TDRs on the HIV phylogeny would imply
frequent emergence in treatment-failing
patients and infrequent transmission,
whereas a strong clustering would suggest
long transmission chains of TDR. The
authors determined those patterns for
the most frequent TDR mutations against
NRTIs (variants/revertants at amino acid
215 in the reverse transcriptase [RT]),
nonnucleoside reverse transcriptase in-
hibitors (NNRTIs) (103N in RT), and
protease inhibitors (90M in the protease
[PR]). In all 3 cases, they found that the re-
sistance mutations observed in treatment-
naive patients formed large transmission
clusters, suggesting ongoing transmission
in the treatment-naive population rather
than frequent emergence in treatment-
failing patients. This was further assessed
in the phylodynamic part of the analysis.
Here, the sequence data were used to esti-
mate for the larger TDR transmission
chains their time of origin and the basic
reproductive number, R0. This analysis re-
vealed R0 values clearly >1 (range, 1.3–2.8),
supporting the sustainable transmission of
these TDR strains. Furthermore, most
of these transmission chains originated in
Received 6 May 2015; accepted 9 May 2015; electronically
published 19 May 2015.
Correspondence: Roger D. Kouyos, PhD, Division of Infec-
tious Diseases and Hospital Epidemiology, University Hospital
Zurich, Rämistr 100, CH-8091 Zürich, Switzerland (roger.
kouyos@uzh.ch).
Clinical Infectious Diseases® 2015;61(5):837–9
© The Author 2015. Published by Oxford University Press on
behalf of the Infectious Diseases Society of America. This is
an Open Access article distributed under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivs
licence (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial reproduction and distribution of
thework, in anymedium, provided theoriginalwork is not altered
or transformed in anyway, and that thework is properly cited. For
commercial re-use, please contact journals.permissions@oup.
com.
DOI: 10.1093/cid/civ400
EDITORIAL COMMENTARY • CID 2015:61 (1 September) • 837
the early 2000s, indicating long-term, on-
going transmission. The clearest case for
treatment-independent transmission is
provided by the 90M mutation in the
protease. The 90M mutation formed the
largest cluster in this study (15 patients),
which originated around 2003, but trans-
mission in this cluster occurred mostly
after 2005. As the drugs (saquinavir and
nelﬁnavir) against which 90M confers re-
sistance were almost out of use by that
time, the clustering of 90M cannot be ex-
plained by several treatment failure
events occurring along the transmission
chain. This of course implies that the
transmission of 90M has no clinical im-
plication beyond being a showcase for
the persistence of resistance mutations
at the population level. The authors
observed, however, similar degrees of
clustering for the 103N mutation, which
is arguably the TDR that leads and will
lead globally to most treatment failures.
The reconstruction and analysis of
transmission chains by molecular meth-
ods allows a unique perspective on the
spread of infectious agents, but it also
has its limitations and this study is no ex-
ception. At the most basic level, there is no
one-to-one relation between sequences
and transmission network—and, accord-
ingly, determining transmission chains
from sequence data depends on ad hoc
thresholds and criteria. For the most part,
these criteria (such as the 1.5% distance
threshold) are well established, but it is
nevertheless important to keep in mind
that alternative—and equally defendable—
criteria would have led to different trans-
mission clusters. More critical for the
present study is that the main phylogenet-
ic analysis was conducted using only se-
quences containing TDR. The omission
of control sequences without TDR implies
that it cannot be excluded that some of the
transmission chains that appear to consist
only of TDR viruses might contain inter-
mediate links consisting of strains without
TDR, which were not included in the an-
alyzed dataset. Such clusters would then
have to be interpreted not as long sustained
transmission chains of TDR, but as several
independent emergence events associated
with treatment failures followed by much
smaller TDR transmission chains. Indeed,
a sensitivity analysis, in which 1000 ran-
domly selected sequences from the UK
Drug Resistance Database were combined
with the 1140 TDR-containing sequences,
exhibited a lower degree of clustering of
TDR. This effect would probably have
been even stronger if the entire UK Drug
Resistance Database (>25 000 subtype B
sequences) would have been included as
controls. Thus, some of the observed clus-
tering is spurious and the length of TDR
transmission chains is probably lower than
estimated by this study.We expect, howev-
er, that this overestimation is not too seri-
ous and that, at least qualitatively, the
ﬁndings are robust to this approximation
( just to mention 2 reasons: ﬁrst, the 1.5%
distance thresholds protects against exces-
sive spurious clustering; second, treatment
failure is generally relatively rare and can
be practically excluded as a source for
90M after 2005). Finally, it should be
noted that the phylodynamic analysis
was only performed for the larger clusters
and, accordingly, the R0 estimates suggest-
ing self-sustained TDR transmission apply
only to these clusters. This implies a selec-
tion bias because large clusters correspond
to those instances where HIV could spread
successfully, whereas small clusters corre-
spond to limited transmission. Hence, the
R0 estimates derived from the large clus-
ters may overestimate the number of sec-
ondary infections caused by one TDR
case in the entire population.
Despite these almost unavoidable limita-
tions of molecular epidemiology, the study
clearly improves and extends the evidence
for sustained treatment-independent trans-
mission of drug-resistant HIV: It conﬁrms
a previous analysis from the Swiss HIV
Cohort Study, which found that 85% of
TDR in men who have sex with men
was transmitted by therapy-naive patients
[5], and adds new types of evidence (R0,
timing of transmission chains). These
ﬁndings have 2 key implications for
HIV public health. First, they support that
a further reduction and eventual elimina-
tion of TDR in industrialized countries
cannot rely only on the prevention of
treatment failure alone but also needs to
address transmission among untreated
individuals. This would thus add one fur-
ther reason in favor of early detection and
treatment of HIV. Second, TDR has ex-
hibited consistent increases in resource-
limited settings over the last years, with
the 103N mutation being the dominant
mutation in terms of both prevalence
and of likely clinical impact. Currently,
ﬁrst-line treatment in almost all of sub-
Saharan Africa relies on NNRTIs, which
would be dramatically affected by a high
prevalence of 103N [9]. The results of the
present study argue for early action to
prevent the spread of this mutation be-
cause its ability to transmit even in the
absence of drug pressure predicts that it
may be very hard to curb it once it (and
any other low-ﬁtness-cost mutation) has
reached a high prevalence. This might
even affect other mutations than the 103N
given that in resource-limited settings viral
load monitoring is scarce and patients
often stay for long periods on failing regi-
mens, leading to extensive accumulation of
resistance mutations [10]. This and the
variability in ﬁtness costs and reversion
rates even for the same TDR in different
genetic backgrounds [6] imply that the
likelihood that in the future even high-ﬁt-
ness-cost mutations may convert into low-
ﬁtness-cost mutations and may be ﬁxed in
these populations should not be underesti-
mated. Hence, strategies to use viral load
monitoring and to use drugs with high ge-
netic barriers earlier need to be explored.
Overall, this study demonstrates the often
underestimated ability of antimicrobial re-
sistance to persist and spread, which un-
derlines the need for early preventive action
while the resistance problem is still small.
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